Oncolytics Biotech Inc T.ONC

ONCY pelareorep selected for Phase 3 Pancreatic Cancer trial

[Noteable]

This is a significant development. PanCAN created the Precision Promise adaptive clinical trial because traditional clinical trial designs are slow to evaluate new treatment options for pancreatic cancer patients. PanCAN’s novel clinical trial platform is designed to more efficiently test new therapies for their effectiveness in treating patients with pancreatic cancer by requiring fewer patients to understand if a potential new therapy is working. The platform is also designed to allow multiple investigational therapies to be tested simultaneously.

https://pancan.org/research/precision-promise/

PanCAN’s Precision Promise Clinical Trial Consortium of over 20 clinical sites were selected through a competitive, peer-review process and include premier cancer treatment institutions across the country.

https://pancan.org/research/precision-promise/locations/

[Noteable]

PanCAN’s Precision Promise Clinical Trial Consortium sites: Baylor College of Medicine (Houston, TX) Principal investigator: Benjamin Musher, MD Cedars-Sinai Medical Center (Los Angeles, CA) Principal investigator: Arsen Osipov, MD Dana-Farber/Harvard Cancer Center (Boston, MA) Principal investigator: Brian Wolpin, MD, MPH Fred Hutch Cancer Center (Seattle, WA

[Capitalista]

This is huge!   PanCAN is the sponsor, so this allows ONC access to a Phase III trial at minimal costs to the company.  Less dilution is required. The fact that PanCAN is the sponsor and invited ONC to join means that the early Goblet results are being taken seriously by influential and knowledgeable players. The Precision Promise trial would be higher profile than the

[Noteable]

With PanCan's selection of ONCY's pelareorep to receive its support for a Phase 3 pancreatic cancer clinical trial in their Precision Promise Adaptive Clinical Trial program, PanCan has selected a bio-platform in choosing pelareorep, and is seeking to apply the repeatable operations of its Precision Promise Adaptive Clinical Trial program that will enable efficiencies, speed, and lower

[Noteable]

From PanCan's website .."Precision Promise is designed to serve as a catalyst to accelerate pancreatic cancer drug development, de-risk industry participation, increase clinical trial enrollment and transform the way clinical research is done for pancreatic cancer patients."

[canadafan]

This is amazing details, thst some are overlooking. it does add value to the company as both a partner or buy- out. BTW, regarding my investment acumen. I have been in stocks etc since 1978. Not once did the number of company shares come into any of my buy/ sell decisions. What did? fruture prospects of the company, Their business in general. dividend payout ratio. Debt coverage ratio

[fox7mf]

$1b buyout with 100m shares would suck...we all know this. Bloating matters.